These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 30855113)

  • 1. Copper Depletion as a Therapeutic Strategy in Cancer.
    Lopez J; Ramchandani D; Vahdat L
    Met Ions Life Sci; 2019 Jan; 19():. PubMed ID: 30855113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Copper deficiency as an anti-cancer strategy.
    Goodman VL; Brewer GJ; Merajver SD
    Endocr Relat Cancer; 2004 Jun; 11(2):255-63. PubMed ID: 15163301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases.
    Chan N; Willis A; Kornhauser N; Ward MM; Lee SB; Nackos E; Seo BR; Chuang E; Cigler T; Moore A; Donovan D; Vallee Cobham M; Fitzpatrick V; Schneider S; Wiener A; Guillaume-Abraham J; Aljom E; Zelkowitz R; Warren JD; Lane ME; Fischbach C; Mittal V; Vahdat L
    Clin Cancer Res; 2017 Feb; 23(3):666-676. PubMed ID: 27769988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of copper status for cancer therapy.
    Goodman VL; Brewer GJ; Merajver SD
    Curr Cancer Drug Targets; 2005 Nov; 5(7):543-9. PubMed ID: 16305350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm.
    Khan G; Merajver S
    Expert Opin Investig Drugs; 2009 Apr; 18(4):541-8. PubMed ID: 19335282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer.
    Henry NL; Dunn R; Merjaver S; Pan Q; Pienta KJ; Brewer G; Smith DC
    Oncology; 2006; 71(3-4):168-75. PubMed ID: 17641535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chelators at the cancer coalface: desferrioxamine to Triapine and beyond.
    Yu Y; Wong J; Lovejoy DB; Kalinowski DS; Richardson DR
    Clin Cancer Res; 2006 Dec; 12(23):6876-83. PubMed ID: 17145804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells.
    Yoshii J; Yoshiji H; Kuriyama S; Ikenaka Y; Noguchi R; Okuda H; Tsujinoue H; Nakatani T; Kishida H; Nakae D; Gomez DE; De Lorenzo MS; Tejera AM; Fukui H
    Int J Cancer; 2001 Dec; 94(6):768-73. PubMed ID: 11745476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.
    Brewer GJ; Merajver SD
    Integr Cancer Ther; 2002 Dec; 1(4):327-37. PubMed ID: 14664727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disulfiram anti-cancer efficacy without copper overload is enhanced by extracellular H2O2 generation: antagonism by tetrathiomolybdate.
    Calderon-Aparicio A; Strasberg-Rieber M; Rieber M
    Oncotarget; 2015 Oct; 6(30):29771-81. PubMed ID: 26356671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel method for rapid copper chelation assessment confirmed low affinity of D-penicillamine for copper in comparison with trientine and 8-hydroxyquinolines.
    Říha M; Karlíčková J; Filipský T; Macáková K; Hrdina R; Mladěnka P
    J Inorg Biochem; 2013 Jun; 123():80-7. PubMed ID: 23563391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is copper chelation an effective anti-angiogenic strategy for cancer treatment?
    Antoniades V; Sioga A; Dietrich EM; Meditskou S; Ekonomou L; Antoniades K
    Med Hypotheses; 2013 Dec; 81(6):1159-63. PubMed ID: 24210000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Biomedical Use of Copper Chelation Therapy.
    Baldari S; Di Rocco G; Toietta G
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32041110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells.
    Daniel KG; Chen D; Orlu S; Cui QC; Miller FR; Dou QP
    Breast Cancer Res; 2005; 7(6):R897-908. PubMed ID: 16280039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment.
    Gupte A; Mumper RJ
    Cancer Treat Rev; 2009 Feb; 35(1):32-46. PubMed ID: 18774652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse.
    Jain S; Cohen J; Ward MM; Kornhauser N; Chuang E; Cigler T; Moore A; Donovan D; Lam C; Cobham MV; Schneider S; Hurtado Rúa SM; Benkert S; Mathijsen Greenwood C; Zelkowitz R; Warren JD; Lane ME; Mittal V; Rafii S; Vahdat LT
    Ann Oncol; 2013 Jun; 24(6):1491-8. PubMed ID: 23406736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The solution structure of the copper clioquinol complex.
    Pushie MJ; Nienaber KH; Summers KL; Cotelesage JJ; Ponomarenko O; Nichol HK; Pickering IJ; George GN
    J Inorg Biochem; 2014 Apr; 133():50-6. PubMed ID: 24503514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chelation therapy in intoxications with mercury, lead and copper.
    Cao Y; Skaug MA; Andersen O; Aaseth J
    J Trace Elem Med Biol; 2015; 31():188-92. PubMed ID: 24894443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutting copper curbs angiogenesis, studies show.
    Vanchieri C
    J Natl Cancer Inst; 2000 Aug; 92(15):1202-3. PubMed ID: 10922401
    [No Abstract]   [Full Text] [Related]  

  • 20. Copper-lowering agents as an adjuvant in chemotherapy.
    Kadu P; Sawant B; Kale PP; Prabhavalkar K
    Indian J Pharmacol; 2021; 53(3):221-225. PubMed ID: 34169907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.